Study reveals new mutations that make cancer resistant to KRAS-targeted therapies

A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year.

Tags: Health, U S Food and Drug Administration, KRAS